• 1703 Citations
  • 26 h-Index
1989 …2023

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Area of Expertise

The focus of my research has two broad aims.
The first aim is to screen compounds that will attenuate the subjective and reinforcing effects of abused drugs as part of a NIDA-funded contract searching for effective treatment drugs for addiction to cocaine, methamphetamine, nicotine, and marijuana.
The second aim is to evaluate the potential abuse liability of novel designer drugs that are increasingly available as "legal" alternatives to controlled substances. We use drug discrimination procedures which assess the subjective effects of common drugs of abuse such as cocaine, methamphetamine, nicotine, and marijuana, with designer drugs like MDMA (Ecstasy), with opioids like morphine, or with hallucinogens like LSD. We also test the reinforcing/rewarding effects of drugs using the conditioned place preference and self-administration assays.

Education/Academic qualification

PhD in Psychology , Utah State University

Award Date: 1 Jan 2002

MA in Behavior Science, University of Houston

Award Date: 1 Jan 2001

BA in Behavioral Science, The University of Chicago

Award Date: 1 Jan 2000

Fingerprint Dive into the research topics where Michael Gatch is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Research Output

  • 1703 Citations
  • 26 h-Index
  • 61 Article
  • 7 Review article
  • 1 Comment/debate
  • 1 Short survey

Cannabinoid-like effects of five novel carboxamide synthetic cannabinoids

Gatch, M. B. & Forster, M. J., Jan 2019, In : NeuroToxicology. 70, p. 72-79 8 p.

Research output: Contribution to journalArticle

  • 6 Scopus citations
  • 1 Scopus citations

    Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor

    Baladi, M. G., Forster, M. J., Gatch, M. B., Mailman, R. B., Hyman, D. L., Carter, L. P. & Janowsky, A., 1 Aug 2018, In : Journal of Pharmacology and Experimental Therapeutics. 366, 2, p. 367-376 10 p.

    Research output: Contribution to journalArticle

  • 15 Scopus citations
  • 3 Scopus citations